18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1501-1510

  Salaun, Pierre Yves ^a   Campion, Loïc ^b   Ansquer, Catherine ^c   Frampas, Eric ^c,d   Mathieu, Cédric ^c   Robin, Philippe ^a   Bournaud, Claire ^e   Vuillez, Jean Philippe ^f   Taieb, David ^g   Rousseau, Caroline ^b,d   Drui, Delphine ^c   Mirallié, Eric ^c   Borson Chazot, Françoise ^e   Goldenberg, David M ^h,i   Chatal, Jean François ^j   Barbet, Jacques ^d,j   Kraeber Bodéré, Françoise ^b,c,d,k  

^a BREST UNIVERSITY HOSPITAL   (France)

^b UMR INSERM U892 CNRS 6299   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e University Hospital   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g University Hospital   (France)

^h IMMUNOMEDICS INC   (United States)

ⁱ CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^j GIP Arronax   (France)

^k HÔTEL DIEU   (France)

more..

Author keywords

Calcitonin; CEA; Doubling time; FDG PET; Medullary thyroid carcinoma; Radioimmunotherapy; Surrogate marker; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DI DIETHYL TRIAMINO PENTAACETIC ACID I 131; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISTANT METASTASIS; FEMALE; HUMAN; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; YOUNG ADULT; CARCINOMA, MEDULLARY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; SCINTISCANNING; SECONDARY; THYROID NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84905566807     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2772-0     Document Type: Article

References (36)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-48. (Pubitemid 29019586)
2. Roman S, Lin R, Sosa JA. Prognosis ofmedullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-42. (Pubitemid 44665646)
3. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-48. (Pubitemid 30127676)
4. Tisell LE, Oden A, Muth A, Altiparmak G, Mõlne J, Ahlman H, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093-7. (Pubitemid 38030908)
5. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients withmedullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-84. (Pubitemid 41606528)
6. Giraudet L, Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239-46. (Pubitemid 351298542)
7. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-801.
8. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-30.
9. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-6.
10. Wells Jr SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-41.
11. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-8s. (Pubitemid 29493915)
12. Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006;47:247-55. (Pubitemid 46780889)
13. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-11. (Pubitemid 46622142)
14. Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med. 2012;53:1185-92.
15. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26:3913-5.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-9. (Pubitemid 14202071)
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-50S.
18. Kraeber-Bodéré F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, et al. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med. 2012;53:1836-46.
19. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527-33.
20. Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855-63.
21. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-7. (Pubitemid 350223431)
22. Verbeek HH, Plukker JT, Koopmans KP, Verbeek HH, Plukker JT, Koopmans KP, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53:1863-71.
23. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-66. (Pubitemid 46939960)
24. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82. (Pubitemid 29512308)
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
26. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-8. (Pubitemid 41702624)
27. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-88. (Pubitemid 40279196)
28. Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med. 2009;50:239-49.
29. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;1(25):1753-9. (Pubitemid 46797957)
30. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-23.
31. Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, et al. Clinical radioimmunotherapy - the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720-34.
32. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med. 2007;48:1683-91. (Pubitemid 47572716)
33. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-63.
34. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;4:1019-27.
35. Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010;72:534-42.
36. Chatal JF, Kraeber-Bodéré F, Goldenberg DM, Barbet J. Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time. J Clin Oncol. 2012;30:2165.